# GLP-1 Weight Management Medicine: VA Veterans Study > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/va-veterans-glp-1-weight-management-study/ > **Published:** 2026-04-20T14:32:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:04:22-04:00 > **Clinical Summary:** Explore the VA veterans GLP-1 weight management study showing real-world benefits beyond weight loss in veteran populations. --- GLP-1 Clinical Relevance  #41Contextual Information  Background context; limited direct clinical applicability. ⚕ GLP-1 News  |  CED Clinic Clinical NewsObservational StudyObesity TreatmentGLP-1 Receptor AgonistVeterans Health AdministrationPrimary Care[Weight Management](https://cedclinic.com/cannabis-metabolism-weight-management-science/)Appetite RegulationMedicare Coverage PolicyReal-World EvidenceMilitary Veteran Population[Metabolic Health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/) Outcomes Why This Matters Family medicine clinicians managing patients on GLP-1 therapy must now navigate coverage gaps created by the Medicare exclusion for weight loss indications, which directly affects treatment continuity for a large segment of the primary care population. This policy shift increases the likelihood that clinicians will need to document comorbid indications such as type 2 diabetes or cardiovascular disease to justify continued prescribing under covered diagnoses. The VA data reinforces the systemic benefit of GLP-1 therapy beyond glycemic control, which strengthens the clinical rationale for pursuing alternative coverage pathways rather than discontinuing treatment. Clinical Takeaway In a real-world VA clinic setting, veterans treated with GLP-1 receptor agonists for weight loss showed broad improvements across multiple health markers after one year, reinforcing that the benefits of these medications extend well beyond the scale. The findings align with growing clinical evidence that GLP-1 therapy positively affects cardiometabolic risk factors, including blood pressure, blood sugar, and lipid profiles, even in complex patient populations. These results are particularly meaningful because VA patients often carry significant comorbidity burdens, making the observed outcomes more generalizable to typical family medicine panels. When counseling patients concerned about access or cost following Medicare coverage changes, clinicians can use real-world data like this to reinforce that the therapeutic value of GLP-1s is well-documented, and that exploring alternative coverage pathways or manufacturer assistance programs is worth pursuing before discontinuing therapy. Dr. Caplan’s Take “The VA data here is exactly what we keep seeing in real-world clinical practice: when patients with obesity get access to GLP-1 therapy and stick with it, the downstream metabolic and cardiovascular improvements are substantial and consistent. The timing of this publication is important, because the Trump administration’s decision to block Medicare coverage for weight loss indications isn’t just a policy disagreement, it’s a direct contradiction of the evidence base these veterans just helped build. In my practice, I use findings like these to have honest conversations with patients about why their insurance may be working against their health, and to help them understand the long-term cost of untreated obesity versus the short-term discomfort of fighting for access. When patients hear that real people in a structured program saw broad systemic improvement after one year, it reframes the conversation from ‘a weight loss drug’ to ‘metabolic medicine with meaningful outcomes.’” Clinical Perspective This VA-based real-world outcomes data reinforces what randomized trials have already suggested: GLP-1 receptor agonists deliver meaningful cardiometabolic benefits well beyond weight reduction alone, and veteran populations with high rates of obesity-related comorbidities stand to gain substantially from sustained access. The timing is clinically significant given the federal rollback of Medicare coverage for weight-loss indications, which threatens to strand a large population of patients who lack alternative coverage pathways. Clinicians should proactively audit their panels for patients who qualify under an established cardiometabolic indication such as type 2 diabetes or established cardiovascular disease, as these diagnoses continue to support coverage and can anchor the prescription independently of weight loss as a primary goal. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20A%20VA%20Clinic%20Gave%20Veterans%20GLP-1s%20for%20Weight%20Loss.%20A%20Year%20Later%2C%20Everything%20Impro%20%40drcaplan&url=https%3A%2F%2Fwww.military.com%2Fbenefits%2Fveterans-health-care%2Fva-clinic-gave-veterans-glp-1s-weight-loss-year-later-everything-improved.html)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.military.com%2Fbenefits%2Fveterans-health-care%2Fva-clinic-gave-veterans-glp-1s-weight-loss-year-later-everything-improved.html)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20A%20VA%20Clinic%20Gave%20Veterans%20GLP-1s%20for%20Weight%20Loss.%20A%20Year%20Later%2C%20Everything%20Impro%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fwww.military.com%2Fbenefits%2Fveterans-health-care%2Fva-clinic-gave-veterans-glp-1s-weight-loss-year-later-everything-improved.html)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/glp-1-news/feed/) 📰 Source: [https://www.military.com/benefits/veterans-health-care/va-clinic-gave-veterans-glp-1s-weight-loss-year-later-everything-improved.html](https://www.military.com/benefits/veterans-health-care/va-clinic-gave-veterans-glp-1s-weight-loss-year-later-everything-improved.html) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What are GLP-1 medications?](#What_are_GLP-1_medications) - [What did the VA study find about veterans taking GLP-1 medications for weight loss?](#What_did_the_VA_study_find_about_veterans_taking_GLP-1_medications_for_weight_loss) - [Why did Medicare stop covering GLP-1 drugs for weight loss?](#Why_did_Medicare_stop_covering_GLP-1_drugs_for_weight_loss) - [If Medicare no longer covers my GLP-1 for weight loss, can I still get it covered for another reason?](#If_Medicare_no_longer_covers_my_GLP-1_for_weight_loss_can_I_still_get_it_covered_for_another_reason) - [Are GLP-1 medications safe for long-term use?](#Are_GLP-1_medications_safe_for_long-term_use) - [What health conditions besides weight loss can GLP-1 drugs help with?](#What_health_conditions_besides_weight_loss_can_GLP-1_drugs_help_with) - [How long does it take to see results on a GLP-1 medication?](#How_long_does_it_take_to_see_results_on_a_GLP-1_medication) - [What happens if I stop taking my GLP-1 medication?](#What_happens_if_I_stop_taking_my_GLP-1_medication) - [Are there affordable alternatives to brand-name GLP-1 medications?](#Are_there_affordable_alternatives_to_brand-name_GLP-1_medications) - [Should I ask my doctor about GLP-1 therapy even if I do not have diabetes?](#Should_I_ask_my_doctor_about_GLP-1_therapy_even_if_I_do_not_have_diabetes) - [Related](#Related) ## FAQ #### What are GLP-1 medications? GLP-1 medications are a class of drugs that mimic a naturally occurring hormone in the body called glucagon-like peptide-1. They work by regulating blood sugar, reducing appetite, and slowing digestion. Doctors use them to treat type 2 diabetes and, increasingly, obesity and related metabolic conditions. #### What did the VA study find about veterans taking GLP-1 medications for weight loss? The VA clinic study found that after one year of GLP-1 therapy, veterans experienced improvements across multiple health measures beyond just weight loss. These included better blood sugar control, blood pressure, and other markers of metabolic health. #### Why did Medicare stop covering GLP-1 drugs for weight loss? In April 2025, the Trump administration reversed a Biden-era decision and announced that Medicare would no longer cover GLP-1 medications specifically for weight loss. This policy change affects Medicare beneficiaries who rely on these drugs primarily for obesity treatment rather than for an approved condition like type 2 diabetes. #### If Medicare no longer covers my GLP-1 for weight loss, can I still get it covered for another reason? Medicare does still cover GLP-1 medications when they are prescribed for approved indications such as type 2 diabetes or, in some cases, cardiovascular disease risk reduction. Your doctor can review your medical history to determine whether you qualify for coverage under a different diagnosis. #### Are GLP-1 medications safe for long-term use? Current clinical evidence supports the safety of GLP-1 medications over extended periods, with large trials running up to several years showing sustained benefits and a well-characterized side effect profile. The most common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) are gastrointestinal, including nausea and vomiting, which often improve over time. Your physician will monitor you regularly to assess both safety and effectiveness. #### What health conditions besides weight loss can GLP-1 drugs help with? GLP-1 medications have demonstrated benefits for type 2 diabetes, cardiovascular disease risk reduction, kidney disease progression, and [metabolic syndrome](https://cedclinic.com/cannabidiol-fatty-liver-disease-research-insights/). Some research also suggests potential benefits for conditions such as [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) and obstructive sleep apnea. #### How long does it take to see results on a GLP-1 medication? Most patients begin to notice reduced appetite and some initial weight loss within the first four to eight weeks of treatment. Meaningful improvements in blood sugar, blood pressure, and other metabolic markers typically become measurable within three to six months. The VA data suggests that a full year of therapy produces more comprehensive health improvements. #### What happens if I stop taking my GLP-1 medication? Clinical studies consistently show that a significant portion of lost weight returns after discontinuing GLP-1 therapy, because these medications manage a chronic condition rather than cure it. Many metabolic improvements can also diminish after stopping the drug. Your doctor can help you make an informed decision about whether long-term or indefinite treatment is appropriate for your situation. #### Are there affordable alternatives to brand-name GLP-1 medications? Compounded versions of GLP-1 medications became available during periods of drug shortage, though their regulatory status and quality standards differ from FDA-approved brand-name products. Some patient assistance programs offered by manufacturers can reduce out-of-pocket costs significantly. Discussing all available options with your physician and a pharmacist is the best way to find a financially sustainable treatment plan. #### Should I ask my doctor about GLP-1 therapy even if I do not have diabetes? Yes, GLP-1 medications are now FDA-approved for chronic [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) in adults with obesity or overweight with at least one weight-related health condition, independent of a diabetes diagnosis. The VA findings reinforce that the benefits of these medications extend well beyond blood sugar control. A consultation with your physician can help determine whether you are a good candidate based on your overall health profile and coverage options. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1 Weight Loss: Semaglutide vs Tirzepatide Evidence](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) Compare clinical evidence on semaglutide and tirzepatide for weight loss to understand their effectiveness and safety profiles. [Read More](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) [GLP-1 Receptor Agonist Clinical Evidence for Weight Management](https://cedclinic.com/glp-1-receptor-agonist-clinical-evidence-for-weight-management/) Review clinical trial data supporting GLP-1 receptor agonists in managing weight and improving metabolic health. [Explore Insights](https://cedclinic.com/glp-1-receptor-agonist-clinical-evidence-for-weight-management/) [GLP-1 Drugs: Clinical Evidence & Patient Outcomes](https://cedclinic.com/glp-1-receptor-agonist-adoption-trends-clinical-evidence/) Understand patient outcomes and clinical evidence for GLP-1 drugs in treating obesity and related conditions. [Learn More](https://cedclinic.com/glp-1-receptor-agonist-adoption-trends-clinical-evidence/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).